Synapse

Synapse is your gateway to discovering essential legal insights tailored for international pharma, biotech, and medical device companies. Our leading International Life Sciences team connects you to the latest developments on the topics that matter, including advertising, AI, product liability, regulatory compliance, data and more.

Life sciences advertising

Synapse is our newly launched newsletter and content hub for legal insights tailored to international pharma, biotech, and medical device companies. This first edition delves into advertising regulations for pharmaceutical and medical device companies, covering social media best practices, European guidelines to advertising medicines and an overview of national penalties for breach of medical device advertising rules.
View edition

Life sciences & healthcare

Our Life Sciences and healthcare team work with some of the largest pharmaceutical, biotechnology, and medical device companies and healthcare providers in the world to a diverse collective of small-to-medium-sized start-up enterprises ready to upscale their business, and many companies in between.

Find out more
Find out more
Advertising Medical Devices

Advertising Medical Devices European Comparison Tool

Looking to promote your medical device products in Europe? Access our comparison tool to manage regulatory challenges across multiple jurisdictions.

Access here
Access here
UPC

The Unified Patent Court (UPC)

The UPC and Unitary Patent will introduce the most radical changes to patent litigation in Europe in 40 years.

Read our guide to the UPC
Read our guide to the UPC

All insights

Filters

Synapse - Life sciences advertising

Beginner's guide to medicines advertising in Europe

Regulatory oversight in Europe strictly governs pharmaceutical advertising, including content, presentation, and audience, although with some variation between countries. Compliance with these regulations is essential to avoid sanctions and third-party damages claims.

10 December 2024

by Nicholas Vollers

2 of 4 Insights

Click here to find out more
Synapse - Life sciences advertising

National penalties for breach of medical device advertising rules

Penalties for breaching advertising laws for medical devices or IVDs in Europe include administrative fines, criminal fines, and damages for unfair competition, but with huge variation between countries. Compliance with local laws is crucial to avoid sanctions and third party damages claims.

10 December 2024

by multiple authors

3 of 4 Insights

Click here to find out more
Synapse - Life sciences advertising

Can medical devices be advertised on social media in Europe?

Advertising medical devices on social media in Europe is complex, requiring compliance with diverse national regulations and careful planning to avoid legal pitfalls.

10 December 2024

by multiple authors

1 of 4 Insights

Click here to find out more
Synapse - Life sciences advertising

Taking care around use of social media for medicines companies

Pharmaceutical companies must exercise caution when using social media for advertising in Europe. Compliance with diverse national laws, transparency in promotional activities, and careful planning are essential.

10 December 2024

by multiple authors

4 of 4 Insights

Click here to find out more
Synapse - Archive

Orphan drug protection

5 December 2024

1 of 9 Insights

Click here to find out more
Synapse - Archive

To use or not to use?

28 November 2024

2 of 9 Insights

Click here to find out more
Synapse - Archive

Updated post-market surveillance (PMS) rules for medical devices in the UK: differences from the EU regulations

13 November 2024

3 of 9 Insights

Click here to find out more
Synapse - Archive

Reporting clinical trial results to the market

24 October 2024

4 of 9 Insights

Click here to find out more
Synapse - Archive

European Court of Justice on advertising for biocidal products: ‘Skin-friendly’ is misleading and violates EU law

19 September 2024

5 of 9 Insights

Click here to find out more